OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile

被引：1
|
作者：
Shia, Chi-Sheng
Wen, Shih-Ni
Hsu, Ren-Yu
Tu, Jyy-Shiuan
Chang, Hui-Wen
Li, Wan-Fen
Lai, Ming-Tain
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7179
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7179
引用
收藏
页数：2
相关论文
共 9 条
  • [1] OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models
    Li, Wan-Fen
    Chiang, Ming-Feng
    Weng, Hao-Cheng
    Yang, Jhih-Jie
    Wu, Hsin-Shan
    Lin, Chun-Jung
    Chiu, Ping-Tzu
    Lai, Ming-Tain
    CANCER RESEARCH, 2024, 84 (06)
  • [2] OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models
    Li, Wan-Fen
    Chiang, Ming-Feng
    Weng, Hao-Cheng
    Yang, Jhih-Jie
    Wu, Hsin-Shan
    Wu, Szu-Yu
    Chen, Yu-Jung
    Lu, Chi-Huan
    Tu, Jyy-Shiuan
    Hsu, Ren-Yu
    Shia, Chi-Sheng
    Huang, Teng-Yi
    Lai, Ming-Tain
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (02) : 163 - 175
  • [3] In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI992
    Kuo, Tzer-Min
    Chang, Ting-Yu
    Huang, Jye-Yu
    Tang, Wei-Chien
    Lin, Chun-Jung
    Wu, Yi-Chen
    Lu, Chi-Huan
    Weng, Hao-Cheng
    Chen, Yu-Jung
    Tsao, Yu-Hsuan
    Wei, Cheng-Yen
    Shen, Lifen
    Li, Wan-Fen
    Lai, Ming-Tain
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
    McNamara, Blair
    Greenman, Michelle
    Bellone, Stefania
    Santin, Luca A.
    Demirkiran, Cem
    Mutlu, Levent
    Hartwich, Tobias Max Philipp
    Yang-Hartwich, Yang
    Ratner, Elena
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2024, 189 : 16 - 23
  • [5] Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma
    Mcnamara, Blair
    Greenman, Michelle
    Bellone, Stefania
    Demirkiran, Cem
    Mutlu, Levent
    Hartwich, Tobias
    Yang-Hartwich, Yang
    Ratner, Elena
    Schwartz, Peter
    Santin, Alessandro
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A91 - A91
  • [6] Combination of TROP2 and SLFN11 as the sensitivity biomarkers for DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd
    Yasuda, Satoru
    Okajima, Daisuke
    Toki, Tadashi
    Yamaguchi, Junko
    Karibe, Tsuyoshi
    Fujitani, Tomomichi
    Nakada, Takashi
    Noguchi, Yutaka
    Murakami, Masato
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [7] BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts
    Yao, Sufei
    Shang, Chengzhang
    An, Gao
    Guo, Chaoshe
    An, W. Frk
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
  • [8] DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
    Okajima, Daisuke
    Yamaguchi, Junko
    Kitamura, Michiko
    Kamei, Reiko
    Maejima, Takanori
    Shibutani, Tomoko
    Yasuda, Satoru
    Toki, Tadashi
    Karibe, Tsuyoshi
    Fujitani, Tomomichi
    Nakada, Takashi
    Goto, Riki
    Noguchi, Yutaka
    Abe, Yuki
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [9] The Trop-2-targeting antibody drug conjugate DB-1305 has higher anti-tumor activity and a potentially better safety profile compared with DS-1062
    Zhang, Y.
    Li, B.
    Shi, R.
    Qiu, Y.
    Zhong, C.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S91 - S92
1